One of the other recommendations on the WHO, there was the proposed addition of the footnote on the Timetable I segment of the Conference, stating that preparations containing predominantly cannabidiol and not much more than 0.2 per cent of delta-nine-tetrahydrocannabinol usually are not under Inter